NCT02115165 2026-04-06
CABA-GCT
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Completed
Clinical Trials
9 trialsNCT03158064 2026-01-28
Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04876456 2026-01-15
A Phase II Trial of Cabozantinib With Patients With Refractory GCTs
Indiana University
Phase 2 Active not recruiting
NCT05634785 2026-01-09
CD30 CAR for CD30+ NSGCT
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT06418789 2025-08-03
GERMAN
N.N. Petrov National Medical Research Center of Oncology
Phase 2 Recruiting
NCT04804007 2025-04-18
Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT
Indiana University
Phase 2 Recruiting
NCT02499952 2022-07-11
Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors
Hoosier Cancer Research Network
Phase 2 Terminated
NCT02317393 2020-07-09
TERMATEP
Centre Francois Baclesse
Phase 2 Completed
NCT02689219 2019-12-10
Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors
Indiana University
Phase 2 Terminated